CM Biomaterials

CM Biomaterials is a biotechnology company focused on developing advanced drug delivery systems for central nervous system (CNS) disorders and oncology. The company utilizes proprietary polymeric biomaterials, including injectable hydrogels and nanoparticles, to provide sustained and localized delivery of therapeutic agents. Their primary research programs target spinal cord injury, traumatic brain injury, and glioblastoma, aiming to improve functional recovery and reduce secondary damage. By delivering drugs directly to the site of injury or disease, the company's technology seeks to overcome the blood-brain barrier and minimize systemic side effects.